Targeting the innate immune system in treating hepatitis B: prospects for functional cure
Clinical and Molecular Hepatology · 01.01.2026 · 32 (1) · 184-199
DOI: 10.3350/cmh.2025.0935 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.01.2026. Verfasst von Karen Cheuk-Ying Ho und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B virus, Immunity, Innate, Antiviral Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Echosesns and MSD, AstraZeneca, Alexion Pharmaceuticals.
Abstract (Originalsprache)
Chronic hepatitis B (CHB) infection remains a significant global public health concern. Functional cure, defined as hepatitis B surface antigen seroclearance with unquantifiable HBV DNA at 24 weeks off treatment, is a desirable endpoint in the treatment of CHB, yet challenging to achieve. Given the limitations of current therapies including nucleos(t)ide analogues and pegylated interferon alpha, novel agents targeting functional cure are emerging. As hepatitis B virus (HBV) is a non-cytolytic virus, liver damage stems from the host immune response towards HBV-infected cells. The innate immune response during the initial phase of HBV infection is crucial in establishing an adequate level of immunity against the virus. However, HBV adopts various mechanisms to evade the host’s innate immunity, partly contributing to the chronicity of infection. This article provides a comprehensive review on how the HBV life cycle interacts with the host’s innate immune system. The latest evidence of novel agents targeting the innate immunity will also be covered. Retinoic acid inducible gene I agonists, toll-like receptor agonists, and interferons are therapies that target the HBV evasion strategies against host’s innate immunity. While small interfering RNAs and antisense oligonucleotides are originally designed for antigen knockdown and reinvigoration of the adaptive immune response, they have also shown additional impacts on the innate immunity. With ongoing research and innovation in combination strategies, advancement in the management of CHB is anticipated in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.
- State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Förderung
- Echosesns and MSD
- AstraZeneca
- Alexion Pharmaceuticals
- Boehringer Ingelheim
- Pfizer
- Ribo Life Science
- Gilead Sciences
- AbbVie
Zitieren
APA
Ho, K. C., Hui, R. W., Seto, W. K., Yuen, M. F., & Mak, L. Y. (2026). Targeting the innate immune system in treating hepatitis B: prospects for functional cure. Clinical and Molecular Hepatology, 32(1), 184-199. https://doi.org/10.3350/cmh.2025.0935
Vancouver
Ho KC, Hui RW, Seto WK, Yuen MF, Mak LY. Targeting the innate immune system in treating hepatitis B: prospects for functional cure. Clinical and Molecular Hepatology. 2026;32(1):184-199. doi:10.3350/cmh.2025.0935
BibTeX
@article{Ho2026,
author = {Ho, Karen Cheuk-Ying and Hui, Rex Wan-Hin and Seto, Wai-Kay and Yuen, Man-Fung and Mak, Lung-Yi},
title = {Targeting the innate immune system in treating hepatitis B: prospects for functional cure},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {1},
pages = {184--199},
doi = {10.3350/cmh.2025.0935}
}
EUVIMED